IGF‐1 as screening tool for acromegaly and adult‐onset growth hormone deficiency in the Netherlands
Authors' conclusion
Highly variable diagnostic and treatment outcomes in acromegaly and AGHD in the Netherlands can be attributed to increased variability of IGF-1 upon conversion to SD scores and low adherence to clinical guidelines.
Study context
- Population
- Patients suspected of or in follow-up for acromegaly or adult-onset GHD; laboratory specialists and endocrinologists in the same centres, the Netherlandsfive patient cases
- Outcome
- Interlaboratory variation of IGF-1
Methodological detailsfive real patient cases with accompanying blood samples, laboratory and medical questionnaires
- Five real patient cases with accompanying blood samples
- Laboratory and medical questionnaires
Main finding
As reported in the abstract
Interlaboratory CV of IGF-1 concentrations (limited variation despite different use of harmonization sample and factor)
13.8 ± 2.8
Interlaboratory CV after conversion to SD scores (increased, due to different reference value sets)
15.7 ± 40.7
Original publication
IGF‐1 as screening tool for acromegaly and adult‐onset growth hormone deficiency in the Netherlands. Clin Endocrinol (Oxf). Published 4 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →